Oral Semaglutide Sheds Pounds; USPSTF Taking Obesity Comments; Plant Extract for T2D

Once-daily 50-mg oral semaglutide helped adults with overweight or obesity achieve 15.1% weight loss — or 17.4% weight loss with full treatment adherence — in the phase IIIa OASIS 1 trial, said Novo Nordisk. A 7-mg and 14-mg version of oral semaglutide is currently approved for type 2 diabetes under the name Rybelsus.

Falling in line with previous studies, a Bavarian study showed that a diagnosis of COVID-19 was tied to an increased incidence of type 1 diabetes in children. (JAMA)

The U.S. Preventive Services Task Force (USPSTF) is currently taking public comments on its draft research plan for weight-loss interventions to prevent obesity-related morbidity and mortality in adults.

Midlife women with prediabetes — a fasting glucose between 100 to 125 mg/dL — had a 120% greater risk for fracture during and after the menopause transition compared with women free of diabetes. (JAMA Network Open)

Totum 63, an investigational combination of five plant extracts, significantly reduced fasting blood glucose in people with prediabetes and early-stage untreated type 2 diabetes in the phase II/III REVERSE-IT trial, Valbiotis announced.

The weight-loss drug semaglutide (Wegovy) may lower the risk of heart disease, early trial results suggested. (Reuters)

An increasing number of workplaces are becoming more “menopause friendly.” (New York Times)

Do soft contact lenses contain toxic forever chemicals? (The Hill)